Source study found

Story checked

Scientists may have found a way to keep your bones strong for life | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-04-06

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Scientists may have found a way to keep your bones strong for life | ScienceDaily

sciencedaily.com · 2026-04-06

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

3 supported
1 not covered

Open claim evidence

The source study

The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation

Signal Transduction and Targeted Therapy · 2025Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredMice with genetic changes that disrupt GPR133 developed low bone density early in life, resembling osteoporosis in humans.View evidenceHide evidence

As statedearly in life

Why this verdict

The abstract supports that constitutive and osteoblast-specific Gpr133/Adgrd1 disruption in mice causes reduced cortical bone mass, altered trabecularization, and an osteopenic/osteoporosis-like phenotype. However, the story’s specific timing claim that this occurred “early in life” is not verifiable from the abstract-level profile; the profile explicitly notes that the timeline of phenotypic development is not detailed in the abstract.

Study evidence

Constitutive and osteoblast-specific Gpr133/Adgrd1 knockout in mice causes reduced cortical bone mass and altered trabecularization in femurs and vertebrae; this osteopenic phenotype is driven by impaired osteoblast function with secondary increases in osteoclast activity.

“Constitutive and osteoblast-specific knockouts of Gpr133/Adgrd1 in mice lead to reduced cortical bone mass and trabecularization in the femurs and vertebrae”

Study evidence

Loss of Gpr133/Adgrd1 in mice (constitutive and osteoblast-specific KO) produces reduced cortical bone mass and decreased trabecularization in femurs and vertebrae, an osteopenic phenotype that the authors ascribe to impaired osteoblast function with a secondary increase in osteoclast activity.

“This osteopenic phenotype in receptor-deficient mice is caused by impaired osteoblast function, which, in turn, promotes increased osteoclast activity.”

Claim 2 of 4SupportedResearchers identified the receptor GPR133 as a powerful regulator of bone strength.View evidenceHide evidence

As statedpowerful regulator

Why this verdict

The abstract-level profile supports GPR133/ADGRD1 as an important regulator of mouse bone biology: loss of the receptor causes an osteopenic/osteoporosis-like skeletal phenotype, and pharmacologic activation enhances osteoblast function and alleviates osteoporosis in a mouse model. The word “powerful” is qualitative and not backed by effect sizes at abstract depth, but the central framing that GPR133 regulates bone strength/bone formation is supported.

Study evidence

“Constitutive and osteoblast-specific knockouts of Gpr133/Adgrd1 in mice lead to reduced cortical bone mass and trabecularization in the femurs and vertebrae”

Study evidence

“This osteopenic phenotype in receptor-deficient mice is caused by impaired osteoblast function, which, in turn, promotes increased osteoclast activity.”

Claim 3 of 4SupportedActivating GPR133 with the newly discovered compound AP503 boosted bone density in mice and counteracted osteoporosis-like damage.View evidenceHide evidence

Why this verdict

The paper profile supports a causal mouse-intervention claim: activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function/differentiation in vitro and in vivo and significantly alleviates osteoporosis in an ovariectomy mouse model. The exact wording “boosted bone density” and “newly discovered” are not quantitatively detailed in the abstract profile, but the main claim that AP503 activation improved bone-related outcomes and counteracted osteoporosis-like pathology in mice is supported.

Study evidence

Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vitro.

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

Study evidence

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vivo (as stated in the abstract).

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

Claim 4 of 4SupportedThe study suggests AP503 could potentially be developed into a treatment that prevents bone loss and rebuilds weakened bone, but more research is needed before human testing.View evidenceHide evidence

As statedcould potentially

Why this verdict

As a hedged translational claim, this is supported by the abstract-level profile. The paper reports that AP503 activates GPR133/ADGRD1, enhances osteoblast function/differentiation, and significantly alleviates osteoporosis in an OVX mouse model, which supports discussing GPR133 activation as a potential therapeutic route for low bone mass. The story’s caveat that further research is needed before human testing is appropriate because the profile contains mouse and in vitro evidence, not direct human treatment evidence.

Study evidence

Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vitro.

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

Study evidence

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vivo (as stated in the abstract).

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The paper attributes the knockout phenotype to impaired osteoblast function with secondary increases in osteoclast activity.
The story reports low bone density and osteoporosis-like outcomes but does not convey the osteoblast/osteoclast remodeling mechanism that the abstract identifies as the cause of the phenotype.
From in vivo animal
GPR133/ADGRD1 is reported to regulate osteoblast differentiation/function through combined activation by PTK7 and mechanical forces, supported by in vitro stretch assays and an in vivo mechanical loading experiment.
The story focuses on GPR133 as a bone-strength regulator and on AP503 treatment potential, but it does not mention the PTK7 ligand, mechanosensitive activation, stretch assays, or mechanical loading evidence.
From In vitro cell stretch assays with PTK7 interaction testing; in_vivo_mechanical_loading
GPR133/ADGRD1-mediated osteoblast differentiation is reported to involve cAMP-dependent activation of β-catenin signaling.
The intracellular signaling mechanism is a material mechanistic element of the paper profile but is not reflected in the presented story claims or caveats.
From in vitro pathway analysis
The abstract does not specify the timeline for development of the knockout bone phenotype, including whether low bone density appeared early in life.
The story presents an early-life onset claim, but the abstract-level paper profile explicitly says the timeline of phenotypic development is not detailed, making this detail not verifiable at the requested depth.
From In vivo mouse genetic knockout skeletal phenotyping

3 things the story did carry across

Mouse genetic loss-of-function of Gpr133/Adgrd1 causes an osteopenic/osteoporosis-like skeletal phenotype with reduced cortical bone mass and altered trabecularization.
Pharmacologic activation with AP-970/43482503 (AP503) enhances osteoblast function/differentiation in vitro and in vivo and significantly alleviates osteoporosis in an OVX mouse model.
The evidence is preclinical: mouse models and in vitro experiments; the abstract-level profile does not provide direct human treatment evidence.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalLoss of GPR133/ADGRD1 in mice causes an osteopenic/osteoporosis-like skeletal phenotype due to impaired osteoblast function with secondary increases in osteoclast activity.In vivo mouse genetic knockout skeletal phenotypingExpand

In plain English

Constitutive and osteoblast-specific loss-of-function of Gpr133/Adgrd1 in mice produces an osteopenic/osteoporosis-like skeletal phenotype characterized by reduced cortical bone mass and altered trabecularization in femora and vertebrae. The phenotype is attributed to impaired osteoblast function with secondary increases in osteoclast activity, supporting a physiological role for GPR133/ADGRD1 in promoting bone formation.

Key findings

Constitutive and osteoblast-specific Gpr133/Adgrd1 knockout in mice causes reduced cortical bone mass and altered trabecularization in femurs and vertebrae; this osteopenic phenotype is driven by impaired osteoblast function with secondary increases in osteoclast activity.

“Constitutive and osteoblast-specific knockouts of Gpr133/Adgrd1 in mice lead to reduced cortical bone mass and trabecularization in the femurs and vertebrae”

What this piece can’t prove

Evidence is derived from mouse knockout models; the abstract does not provide direct human experimental confirmation.

2 further details could not be confirmed from the summary.

2in vivo animalLoss of GPR133/ADGRD1 in mice causes an osteopenic/osteoporosis-like skeletal phenotype due to impaired osteoblast function with secondary increases in osteoclast activity.Expand

In plain English

The paper reports that constitutive and osteoblast-specific knockout of Gpr133/Adgrd1 in mice produces an osteopenic phenotype (reduced cortical bone mass and trabecularization in femurs and vertebrae) that the authors attribute to impaired osteoblast function, with a secondary increase in osteoclast activity.

Key findings

Loss of Gpr133/Adgrd1 in mice (constitutive and osteoblast-specific KO) produces reduced cortical bone mass and decreased trabecularization in femurs and vertebrae, an osteopenic phenotype that the authors ascribe to impaired osteoblast function with a secondary increase in osteoclast activity.

“This osteopenic phenotype in receptor-deficient mice is caused by impaired osteoblast function, which, in turn, promotes increased osteoclast activity.”

What this piece can’t prove

2 further details could not be confirmed from the summary.

3in vitroGPR133/ADGRD1 regulates osteoblast differentiation/function via combined activation by an endogenous ligand (PTK7) and mechanical forces (mechanosensitive activation).In vitro cell stretch assays with PTK7 interaction testingExpand

In plain English

The paper reports that in vitro cell stretch assays demonstrate GPR133/ADGRD1 regulates osteoblast differentiation and function via a combined activation mechanism that involves interaction with the endogenous ligand PTK7 together with mechanical stimulation.

Key findings

Stretch assays performed in vitro are reported to show that GPR133/ADGRD1 regulates osteoblast differentiation/function through a combined activation mechanism requiring interaction with PTK7 and mechanical forces.

“At the molecular level, GPR133/ADGRD1 regulates osteoblast function and differentiation through a combined activation mechanism involving interaction with its endogenous ligand, protein tyrosine kinase 7 (PTK7), and mechanical forces.”

What this piece can’t prove

The mechanistic claim (combined activation by PTK7 and mechanical force) is stated but the abstract does not detail causality tests (necessity/sufficiency).

3 further details could not be confirmed from the summary.

4in vivo animalGPR133/ADGRD1 regulates osteoblast differentiation/function via combined activation by an endogenous ligand (PTK7) and mechanical forces (mechanosensitive activation).in vivo mechanical loadingExpand

In plain English

An in vivo mechanical loading experiment in mice was performed and reported as evidence that mechanical forces activate GPR133/ADGRD1 in a living system, affecting osteoblast function and differentiation and supporting a combined activation mechanism with the endogenous ligand PTK7.

Key findings

An in vivo mechanical loading experiment indicates that mechanical forces can activate GPR133/ADGRD1 in mice and that this activation affects osteoblast function and differentiation.

“and in vivo via a mechanical loading experiment.”

What this piece can’t prove

2 further details could not be confirmed from the summary.

5in vitroGPR133/ADGRD1-mediated osteoblast differentiation is driven by cAMP-dependent activation of β-catenin signaling.in vitro pathway analysisExpand

In plain English

The abstract reports that, in vitro, GPR133/ADGRD1 promotes osteoblast differentiation via a mechanism that requires cAMP-dependent activation of β-catenin signaling.

Key findings

GPR133/ADGRD1-mediated osteoblast differentiation is driven by cAMP-dependent activation of the β-catenin signaling pathway (reported from in vitro analyses).

“Further in vitro analysis shows that GPR133/ADGRD1-mediated osteoblast differentiation is driven by cAMP-dependent activation of the β-catenin signaling pathway.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

6in vitroPharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function/differentiation and alleviates osteoporosis in an ovariectomy mouse model.In vitro ligand agonism to assess osteoblast differentiation/functionExpand

In plain English

In vitro pharmacologic activation of the adhesion GPCR GPR133/ADGRD1 with the receptor-specific agonist AP-970/43482503 (AP503) enhanced osteoblast function and differentiation in assays reported in the paper abstract.

Key findings

Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vitro.

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

What this piece can’t prove

Summary is based solely on the paper abstract; methodological and numerical details of the in vitro experiments are not provided there.

2 further details could not be confirmed from the summary.

7in vivo animalPharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function/differentiation and alleviates osteoporosis in an ovariectomy mouse model.in vivo pharmacologic administrationExpand

In plain English

The paper reports that pharmacologic activation of the adhesion GPCR GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vivo (abstract statement). The abstract also states AP503 alleviates osteoporosis in an ovariectomy (OVX) mouse model, but the unit focuses on the claim of in vivo enhancement of osteoblast function/differentiation separate from the disease-model efficacy.

Key findings

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function and differentiation in vivo (as stated in the abstract).

“Activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhances osteoblast function and differentiation, both in vitro and in vivo”

What this piece can’t prove

Unspecified whether the in vivo AP503 experiment was performed in healthy mice or as part of the OVX model.

3 further details could not be confirmed from the summary.

8in vivo animalPharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) enhances osteoblast function/differentiation and alleviates osteoporosis in an ovariectomy mouse model.in vivo animal OVX pharmacologic interventionExpand

In plain English

In an ovariectomy (OVX) mouse model of osteoporosis, pharmacologic activation of GPR133/ADGRD1 with the receptor-specific ligand AP-970/43482503 (AP503) enhanced osteoblast function and differentiation in vivo and 'significantly alleviated osteoporosis' relative to controls (abstract statement).

Key findings

Pharmacologic activation of GPR133/ADGRD1 with AP-970/43482503 (AP503) in an ovariectomy mouse model enhanced osteoblast function/differentiation and significantly alleviated osteoporosis in vivo (abstract statement).